Switching diabetes treatment from dulaglutide to PG-102
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether switching from a common diabetes medication, dulaglutide, to a new one called PG-102 is safe and works well for people with type 2 diabetes. It looks at how the new drug manages blood sugar and any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 75 years old.
- You have had type 2 diabetes for at least 6 months.
- You have been taking dulaglutide (0.75 or 1.5 mg) for at least 12 weeks and have not changed the dose or how often you take it in the last 8 weeks.
- Your blood sugar control (HbA1c) is 7.5% or lower.
- If you take other diabetes pills, your dose has been steady for at least 90 days.
- Your body mass index (BMI) is between 18.5 and 30.0.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called HS-20094 for people with type 2 diabetes. It aims to see if it helps lower blood sugar and may also help with weight. You may be able to join if you are currently on metformin or metformin plus an SGLT-2 inhibitor.
This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.
This study looks at what happens when people with type 2 diabetes switch from a short course of intensive insulin therapy to different daily diabetes medicines. It aims to find which option helps keep blood sugar under control and might be easier for you.
This study tests a new medicine called zenagamtide for adults with overweight or obesity, with or without type 2 diabetes, who are currently taking semaglutide. The goal is to see how well people tolerate switching from semaglutide to the new treatment.
This trial tests if a weekly injection of dulaglutide (Trulicity) can help children with type 2 diabetes control their blood sugar when used together with metformin and/or insulin. It may be an option for kids who are overweight.
This study tests if adding LY3457263 helps lower blood sugar in people with type 2 diabetes who are already taking a stable dose of semaglutide or tirzepatide. You will be randomly assigned to get either LY3457263 or a placebo.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.